MBOT Microbot Medical
- 0.952
- -0.001-0.05%
Microbot Medical News
Microbot Medical's LIBERTY System Success With Corewell Health
Express News | Microbot Medical Announces Positive Results From the First Phase of Its Collaboration With Corewell Health™
Microbot Medical Announces Positive Results From the First Phase of Its Collaboration With Corewell Health
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular proceduresBRAINTREE, Mass., April 29,
Microbot Medical Outlines Regulatory Goals and Investor Cautions
Express News | Microbot Medical Anticipates Receiving 510(K) Clearance From FDA In H1 2025, And CE MARK Approval In H2 2025
Express News | Microbot Medical - Sees Receiving 510(K) Clearance From US Food & Drug Administration in the First Half of 2025, and Ce Mark Approval in H2 of 2025
Express News | HC Wainwright & Co. Maintains Buy on Microbot Medical, Lowers Price Target to $7
Microbot Medical Is Maintained at Buy by HC Wainwright & Co.
Microbot Medical Is Maintained at Buy by HC Wainwright & Co.
Microbot Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 586.27% HC Wainwright & Co. $8 → $7 Maintains Buy 10/18/2023 684.31% HC Wainwright & Co. → $8 R
Express News | Microbot Medical, Inc. : H.c. Wainwright Cuts Target Price to $7 From $8
Microbot Medical Operations Remain on Track Amid Middle East Tensions, Shares up
Express News | Microbot Medical: Activities Both in Israel, USA and Other Parts of the Globe Continue Without Interruption
Express News | Microbot Medical: Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the on-Going Situation in Israel
Express News | Microbot Medical Q4 EPS $(0.26) Misses $(0.25) Estimate
Microbot Medical Files to Sell 1M Shares of Common Stock for Holders
Microbot Files FDA Application for Clinical Study of Liberty System
Express News | Microbot Medical Submits Investigational Device Exemption Application To Gain FDA Approval To Commence Its Pivotal Clinical Trial In The US
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this applicationBRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Me
Looking Into Microbot Medical's Recent Short Interest
Microbot Medical's (NYSE:MBOT) short percent of float has risen 172.0% since its last report. The company recently reported that it has 88 thousand shares sold short, which is 0.68% of all regular sha
Microbot Medical Bolsters Team for Upcoming Clinical Trial
Analysis
Price Target
No Data
